Expression of the SART3 antigens in oral cancers

Kurume Medical Journal

Volumn 48, Issue 1, 2001, Pages 55-58

  Fukuda, Kenji ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cancer vaccine; Cytotoxic T lymphocyte; Oral cancer; SART3 antigen

Indexed keywords

CANCER VACCINE; GAMMA INTERFERON; HLA A ANTIGEN; HLA A24 ANTIGEN; RNA BINDING PROTEIN; SART3 PROTEIN, HUMAN; TUMOR ANTIGEN;

ARTICLE; BIOSYNTHESIS; CELL CULTURE; CYTOTOXIC T LYMPHOCYTE; HUMAN; IMMUNOLOGY; MOUTH TUMOR;

ANTIGENS, NEOPLASM; CANCER VACCINES; HLA-A ANTIGENS; HUMANS; INTERFERON TYPE II; MOUTH NEOPLASMS; RNA-BINDING PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED;

EID: 0035228926     PISSN: 00235679     EISSN: None     Source Type: Journal    
DOI: 10.2739/kurumemedj.48.55     Document Type: Article

References (11)

1. Van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991; 254:1643-1647.
2. Traversari C, Van der Bruggen P, Luescher IF, Lurquin C, Chomez P et al. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J Exp Med 1992; 176:1453-1457.
3. Kawakami Y, Eliyahu S, Sakaguchi K, Robbins PF, Rivoltini L et al. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med 1994; 180:347-352.
4. Gaugler B, Van den Eynde B, Van der Bruggen P, Romero P, Gaforio JJ et al. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J Exp Med 1994; 179:921-930.
5. Robbins PF, El-Gamil M, Li YF, Kawakami Y, Loftus D et al. A mutated β-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J Exp Med 1996; 183:1185-1192.
6. Marchand M, Van Baren N, Weynants W, Brichard V, Dréno B et al. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer 1999; 80:219-230.
7. Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998; 4:321-327.
8. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S et al. Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nat Med 1998; 4:328-332.
9. Yang D, Nakao M, Shichijyo S, Sasatomi T, Takasu H et al. Identification of a gene coding for a protein possessing shared tumor epitopes capable of inducing HLA-A24-restricted cytotoxic T lymphocytes in cancer patients. Cancer Research 1999; 59:4056-4063.
10. Niiya F, Nishizawa S, Matsunaga K, Koufuji K, Mori M et al. Expression of SART3 tumor-rejection antigen in gastric cancers. Jpn J Cancer Res 2000; 91:337-342.
11. Imanishi T, Akazawa T, Kimura A, Tokunaga K, and Gojobori T. Allele and haplotype frequencies for HLA and complement loci in various ethnic groups. In: HLA 1991, ed. Tsuji K, Aizawa M and Sasazuki T, Oxford Scientific Pub, Oxford, Vol. 1, pp 1065-1220, 1992.